Serotonin link to heart valve disease emerges in Columbia research

A Columbia University research team has identified an unexpected biological link between serotonin, the brain chemical most famous for regulating mood, and the progression of a common heart valve disease. The finding suggests that some patients taking SSRI antidepressants—among the most widely prescribed medications in the country—may experience faster deterioration of their mitral valves if they carry a specific genetic variant, potentially requiring surgery at a younger age than their peers.

The mitral valve, a thin membrane between the heart's upper and lower left chambers, functions as a one-way gate. Each heartbeat should seal it firmly, preventing blood from flowing backward into the upper chamber. In degenerative mitral regurgitation, the valve tissue thickens, stretches, or warps until it can no longer close completely. Blood leaks backward, raising pressure toward the lungs and reducing the oxygen-rich blood that flows forward through the body. Early on, patients may feel nothing. As the condition worsens, fatigue and shortness of breath set in. The heart works harder to compensate, and that strain can eventually trigger atrial fibrillation or heart failure. Medications can manage symptoms, but they cannot reverse the underlying damage. Once the valve becomes severely compromised, surgery to repair or replace it becomes necessary.

The Columbia team, working with researchers at Children's Hospital of Philadelphia, the University of Pennsylvania, and the Valley Hospital Heart Institute, began by examining clinical records from more than 9,000 patients who had undergone mitral valve surgery for this disease. They found that patients taking SSRIs—common medications like fluoxetine and sertraline—tended to require surgery at younger ages than those not taking the drugs. The observation raised a question: could the same mechanism that SSRIs use to treat depression also be harming the heart valve?

SSRIs work by blocking a protein called the serotonin transporter, which normally reabsorbs serotonin from the space between nerve cells so it can be recycled. By reducing this reuptake, SSRIs leave more serotonin available for longer, easing mood symptoms. The researchers wondered whether this same reduction in transporter activity might inadvertently damage valve tissue that was already degenerating. To test the idea, they studied transgenic mice lacking the serotonin transporter gene and found their mitral valves thickened abnormally. Normal mice given high doses of SSRIs showed the same effect. In human valve cells, the team discovered that a genetic variant in the serotonin transporter gene—called the "long-long" variant—reduced transporter activity and made cells more sensitive to serotonin. These cells produced excessive collagen, the protein that gives tissue structure. Too much collagen stiffens and thickens the valve, warping its shape and movement.

Patients with degenerative mitral regurgitation who carried the "long-long" variant underwent surgery more frequently than those with other variants. The researchers proposed that for these genetically vulnerable patients, taking an SSRI could further reduce serotonin transporter activity in the valve tissue, accelerating the disease. They suggested that a simple DNA test using a blood sample or mouth swab could identify who might need closer monitoring or earlier intervention. Giovanni Ferrari, the Columbia researcher who led the work, noted that promptly repairing a severely leaky valve could protect the heart and prevent congestive heart failure.

Yet the findings come with important caveats. The patient data showed an association, not proof of cause and effect. Healthy mitral valves appear resistant to low serotonin transporter activity—the damage seems to require a valve that has already begun to degenerate. The research does not suggest that SSRIs generally damage healthy hearts, and stopping or changing antidepressant treatment without medical guidance would be unwise. Since the original 2023 publication, additional studies have broadened the picture. A 2024 study found that mice with deficient serotonin transporter activity developed fibrotic changes not only in the mitral valve but also in the left ventricular heart muscle. A 2025 investigation of aortic stenosis, a different valve disease, found elevated serotonin levels in severely affected patients. Most recently, researchers identified an experimental compound that blocked a serotonin receptor called HTR2B and helped preserve valve structure in mice, suggesting a possible future drug target.

A 2026 meta-analysis pooling data from multiple clinical studies found a significant association between medications that modify serotonin transporter activity and heart valve disease. Yet the authors acknowledged that mechanistic evidence remains limited and that more detailed research is needed to separate the effects of different drugs, doses, treatment durations, and underlying health conditions. For now, the findings offer a compelling biological explanation for why some damaged valves deteriorate faster in certain patients, but they do not yet change standard clinical practice. Genetic testing for the serotonin transporter variant is not routine, and no new treatments have been approved. Patients with degenerative mitral regurgitation continue to rely on regular cardiology care, imaging, and individualized decisions about their medications. The research points toward a future where genetic information might identify vulnerable patients or where targeted drugs could block harmful valve remodeling without disrupting serotonin's many other essential roles in the body—but that future remains contingent on clinical trials that have not yet been conducted.